Palisade Bio, Inc. (PALI)

NASDAQ: PALI · IEX Real-Time Price · USD
0.107
-0.005 (-4.56%)
Sep 27, 2022 2:36 PM EDT - Market closed
-4.56%
Market Cap 7.60M
Revenue (ttm) n/a
Net Income (ttm) -358,000
Shares Out 71.24M
EPS (ttm) 2.73
PE Ratio 0.04
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,557,308
Open 0.115
Previous Close 0.112
Day's Range 0.106 - 0.120
52-Week Range 0.106 - 3.020
Beta n/a
Analysts Buy
Price Target 1.53 (+1,333.9%)
Earnings Date Nov 14, 2022

About PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. Th... [Read more...]

Industry Biotechnology
Founded 1996
CEO Kenneth Carter
Employees 13
Stock Exchange NASDAQ
Ticker Symbol PALI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for PALI stock is "Buy." The 12-month stock price forecast is 1.53, which is an increase of 1,333.93% from the latest price.

Price Target
$1.53
(1,333.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complicati...

3 days ago - GlobeNewsWire

Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET

6 days ago - GlobeNewsWire

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead...

CARLSBAD, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complic...

1 week ago - GlobeNewsWire

Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study ...

Live moderated video webcast with members of Management to discuss pivotal Phase 3 study of lead asset in development, LB1148, on Friday, September 16th at 11:00 AM ET Live moderated video webcast with ...

2 weeks ago - GlobeNewsWire

Palisade Bio, Inc. (PALI) Moves to Buy: Rationale Behind the Upgrade

Palisade Bio, Inc. (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative ...

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complica...

1 month ago - GlobeNewsWire

Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotm...

CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications,...

1 month ago - GlobeNewsWire

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Quarter marked by initiation of Phase 3 study evaluating LB1148 for postoperative return of bowel function Quarter marked by initiation of Phase 3 study evaluating LB1148 for postoperative return of bow...

1 month ago - GlobeNewsWire

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications,...

1 month ago - GlobeNewsWire

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal...

New website aligns with company's mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new standards of patient care in GI health New website...

1 month ago - GlobeNewsWire

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Fu...

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complica...

2 months ago - GlobeNewsWire

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months

2 months ago - GlobeNewsWire

Palisade Bio to Present at the 2022 BIO International Convention

In-person presentation on Monday, June 13th at 1:45 PM PT In-person presentation on Monday, June 13th at 1:45 PM PT

3 months ago - GlobeNewsWire

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022

4 months ago - GlobeNewsWire

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today...

4 months ago - GlobeNewsWire

Palisade Bio Announces $2.0 Million Registered Direct Offering

CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chron...

4 months ago - GlobeNewsWire

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Acc...

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study

4 months ago - GlobeNewsWire

Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Phase 3 study of LB1148 in lead indication for postoperative return of bowel function o...

4 months ago - GlobeNewsWire

Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event

Live moderated video webcast discussion among members of Management and a renowned Key Opinion Leader on Tuesday, May 3rd at 10:00 AM ET Live moderated video webcast discussion among members of Manageme...

4 months ago - GlobeNewsWire

Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted ...

CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complic...

6 months ago - GlobeNewsWire

Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up Today

We're seeing a lot of activity from penny stocks today and have put together a list of the top ones for investors to watch. The post Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up To...

Other symbols: DPROENSVSMFLSPCB
6 months ago - InvestorPlace

FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study

Palisade Bio Inc (NASDAQ: PALI) has received a "Study May Proceed" letter from the FDA for a Phase 3 trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowe...

6 months ago - Benzinga

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1...

CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complic...

6 months ago - GlobeNewsWire

Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update

CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients ...

6 months ago - GlobeNewsWire

Palisade Bio's LB1148 Cuts The Risk of Adhesion Formation By 72% After Bowel Resection Surgery

Palisade Bio Inc (NASDAQ: PALI) announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN), highlighting LB1148 reduced incidence of adhesions by 72% in patients un...

6 months ago - Benzinga